BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019
30 sept. 2019 06h00 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019
26 sept. 2019 18h05 HE | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Persbericht Biocarti
Persbericht Biocartis NV: Vijf Idylla™ performantie studies worden gepresenteerd op het ‘European Society for Medical Oncology’ (ESMO) congres
23 sept. 2019 01h00 HE | Biocartis NV
PERSBERICHT23 september 2019, 07:00 CEST Mechelen, België, 23 september 2019 – Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek...
Press Release Biocar
Press Release Biocartis NV: Five Idylla™ Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress
23 sept. 2019 01h00 HE | Biocartis NV
PRESS RELEASE23 September 2019, 07:00 CEST Mechelen, Belgium, 23 September 2019 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext...